The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
Open accessAbstract
Background: Photoimmunotherapy involves targeted delivery of photosensitizers via an antibody conjugate (i.e., photoimmunoconjugate, PIC) followed by light activation for selective tumor killing. The trade-off between PIC selectivity and PIC uptake is a major drawback limiting the efficacy of photoimmunotherapy. Despite ample evidence showing that photoimmunotherapy is most effective when combined with chemotherapy, the design of nanocarriers to co-deliver PICs and chemotherapy drugs remains an unmet need. To overcome these challenges, we developed a novel photoimmunoconjugate-nanoliposome (PIC-Nal) comprising of three clinically used agents: anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab (Cet), benzoporphyrin derivative (BPD) photosensitizer, and irinotecan (IRI) chemotherapy. Results: The BPD photosensitizers were first tethered to Cet at a molar ratio of 6:1 using carbodiimide chemistry to form PICs. Conjugation of PICs onto nanoliposome irinotecan (Nal–IRI) was facilitated by copper-free click chemistry, which resulted in monodispersed PIC–Nal–IRI with an average size of 158.8 ± 15.6 nm. PIC–Nal–IRI is highly selective against EGFR-overexpressing epithelial ovarian cancer cells with 2- to 6-fold less accumulation in low EGFR expressing cells. Successful coupling of PIC onto Nal–IRI enhanced PIC uptake and photoimmunotherapy efficacy by up to 30% in OVCAR-5 cells. Furthermore, PIC–Nal–IRI synergistically reduced cancer viability via a unique three-way mechanism (i.e., EGFR downregulation, mitochondrial depolarization, and DNA damage). Conclusion: It is increasingly evident that the most effective therapies for cancer will involve combination treatments that target multiple non-overlapping pathways while minimizing side effects. Nanotechnology combined with photochemistry provides a unique opportunity to simultaneously deliver and activate multiple drugs that target all major regions of a cancer cell—plasma membrane, cytoplasm, and nucleus. PIC–Nal–IRI offers a promising strategy to overcome the selectivity-uptake trade-off, improve photoimmunotherapy efficacy, and enable multi-tier cancer targeting. Controllable drug compartmentalization, easy surface modification, and high clinical relevance collectively make PIC–Nal–IRI extremely valuable and merits further investigations in living animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,038
van Dam, G. M., Themelis, G., Crane, L. M. A., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., Sarantopoulos, A., de Jong, J. S., Arts, H. J. G., van der Zee, A. G. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2472 · Cited by 1,545
Gamma-H2AX - a novel biomarker for DNA double-strand breaks.
Kuo, L. J., & Yang, L. (2008) · PubMed · Cited by 1,167
Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L. T., Choyke, P. L., & Kobayashi, H. (2011) · Nature Medicine · doi:10.1038/nm.2554 · Cited by 1,057
Cited by
Exosome engineering in cell therapy and drug delivery
Sadeghi, S., Tehrani, F. R., Tahmasebi, S., Shafiee, A., & Hashemi, S. M. (2023) · Inflammopharmacology · doi:10.1007/s10787-022-01115-7 · Cited by 351
Current status and prospects of metal-organic frameworks for bone therapy and bone repair
Li, M., Yin, S., Lin, M., Chen, X., Pan, Y., Peng, Y., Sun, J., Kumar, A., & Liu, J. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00742h · Cited by 156
Si, K., Dai, Z., Li, Z., Ye, Z., Ding, B., Feng, S., Sun, B., Shen, Y., & Xiao, Z. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.005 · Cited by 60
Abouelnazar, F. A., Zhang, X., Zhang, J., Wang, M., Yu, D., Zang, X., Zhang, J., Li, Y., Xu, J., Yang, Q., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02985-9 · Cited by 24
Metadata
- Authors
- Liang, B. J., Pigula, M., Baglo, Y., Najafali, D., Hasan, T., & Huang, H.-C.
- Venue
- Journal of Nanobiotechnology
- Published
- 2020-01-02
- Volume
- 18
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W3002574173
- Cited by
- 324
- References
- 46
- FWCI
- 21.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting. https://app.cochat.ai/papers/10.1186/s12951-019-0560-5
- The paper
- Liang, B. J., Pigula, M., Baglo, Y., Najafali, D., Hasan, T., & Huang, H.-C. (2020). Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-019-0560-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.